Form 4: Athira Pharma CMO Receives Stock Option Grant

Athira Pharma's Chief Medical Officer, Javier San Martin, was granted 44,508 stock options with an exercise price of $4.07, subject to vesting conditions.

Summary

• Javier San Martin, Chief Medical Officer of Athira Pharma, Inc. (ATHA), was granted an option to purchase 44,508 shares of common stock.
• The grant date for the option was September 24, 2025.
• The exercise price for the stock option is $4.07 per share, which was the closing price on the Nasdaq Global Market on the grant date.
• The option is subject to both a Milestone Requirement and a Service-Based Requirement for vesting.
• The Milestone Requirement was satisfied on December 23, 2025.
• The Service-Based Requirement dictates that 50% of the total shares will vest on December 23, 2026, and 1/36th of the remaining 50% will vest on the 23rd day of each month thereafter, contingent on continued service.
• The stock option has an expiration date of September 23, 2035.

Sentiment

Score: 6

Explanation: The grant of stock options to a key executive is a routine and generally positive event, as it aligns management incentives with shareholder interests. It does not, however, indicate any significant operational or financial news that would dramatically shift sentiment.

Positives

• The grant of stock options aligns the Chief Medical Officer's financial interests with the long-term performance and shareholder value of Athira Pharma.
• This is a standard component of executive compensation, indicating a commitment to retaining key management personnel.

Negatives

• The issuance of new stock options can lead to potential future dilution for existing shareholders if the options are exercised, though this is a common aspect of equity compensation plans.

Risks

• The vesting of the stock options is contingent on both a Milestone Requirement and a Service-Based Requirement, meaning the full benefit is not guaranteed if these conditions are not met.
• The value of the options is subject to the future market price of Athira Pharma's common stock, which can fluctuate.

Future Outlook

The filing does not provide specific forward-looking statements or guidance beyond the vesting schedule of the granted options. It primarily reports a past executive compensation event.

Industry Context

The grant of stock options to a Chief Medical Officer is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key scientific and executive talent. Such equity-based compensation aligns the interests of management with those of shareholders, particularly in companies focused on long-term drug development and milestones.

Comparison to Industry Standards

• The structure of this stock option grant, including vesting based on milestones and service, is consistent with typical executive compensation packages observed across the biotechnology sector. Companies like Biogen Inc. or Amgen Inc. frequently utilize similar equity incentive plans to motivate their leadership teams.
• The exercise price being set at the closing market price on the grant date is a standard practice for 'at-the-money' options, common in many corporate equity plans.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned management incentives.
• Employees (specifically Javier San Martin): Receives significant equity compensation, enhancing retention and motivation.

Next Steps

• The Service-Based Requirement for the option will continue to be satisfied, with 50% vesting on December 23, 2026, and subsequent monthly vesting thereafter, subject to continued service.

Key Dates

Keywords

Athira Pharma, ATHA, stock option, executive compensation, Form 4, insider transaction, Chief Medical Officer, equity incentive plan